Starpharma Holdings Limited · ASX:SPL
Starpharma — Australian Biotechnology Expo 2005
18 slides from Starpharma's conference presentation, Aug 9, 2005
Slide 1: CEO Presentation, Australian Biotechnology Expo
starpharma 9 August 2005 CEO PRESENTATION AUSTRALIAN BIOTECHNOLOGY EXPO Attached is a copy of Dr John W Raff's presentation to the 2005 Emerging Growth Capital Annual Australian Biotechnology Expo, held in conjunction with the Australian Stock Exchange in Sydney today. About Starpharma: Starpharma H
Slide 2: Australian Biotech Expo - Starpharma Holdings Limited
Australian Biotech Expo 9 August 2005 Starpharma Holdings Limited (ASX: SPL) Dr John W. Raff CEO Starpharma
Slide 3: Who is Starpharma?
Who is Starpharma? Business: Globally pre-eminent in the Development and commercialisation of new pharmaceuticals using ‘dendrimers’ (highly defined nano-scale structures) Competitive First and only pharmaceutical development company to have had the Advantage: US Food & Drug Administration (“FDA”) a
Slide 4: Nanotechnology
Nanotechnology Al starp) aria * Purposeful manipulation of matter smaller than 100 nanometres (“nm’). * Nanotechnology will revolutionise manufacturing and pharmaceutical compounds. * Nanotechnology is the largest US Federally funded science initiative since it decided to put a man on the moon. (In
Slide 5: Nanopharmaceuticals
Nanopharmaceuticals We are in the right place at the right time # \ % f . P 5 ° i biotechnology‘ starpharma _nanotechnology / \ % 7 é & y "tag, _ gy ‘aay we we eit "0 seemnmamsnmnnsssioe sO ay ne i al a * “Revenue from nanotechnology-enabled * ¢. 50% of all new drugs derived products to equal IT and
Slide 6: Nanopharmaceuticals: Well-defined structures are everything
Nanopharmaceuticals Well- defined structures are everything: Dendrimers sigh starp arma Regulatory Authorities around the world emphasise that nanostructures must be well defined for medicinal use. Starpharma is a world leader in defined synthetic nanostructures : Dendrimers ‘ . 11 — IP ownership pe
Slide 7: Starpharma's Growth Strategy and Drivers of Value
Starpharma’s Growth Strategy and Drivers of Value Product Focus and Leverage of Shareholders’ Funds © VivaGel™ — Further clinical development; advancement to efficacy trials — Line extensions: Expanded indications (other STIs) and applications (condom coating) New Dendrimer Products through in-house
Slide 8: VivaGel: Topical Vaginal Gel for HIV and STI prevention
VivaGel™ Topical Vaginal Gel for the prevention of HIV and STIs coh starp arma What doesit Safe sex > . offer? * a way for a women to avoid STIs + discrete with broad cultural acceptability * female controlled (unlike condom). How does it Broad spectrum microbicide work? *To prevent the transmission
Slide 9: VivaGel: World's first defined nanopharmaceutical tested in humans
VivaGel™ World’s first defined nanopharmaceutical tested in humans. coh starp arma Development Stage: 2004: Completed initial Phase | (IND). 2005: Expanded clinical program Line Extensions: «Combination products (NIH Funding) «Condom coatings
Slide 10: VivaGel Product Benefits
VivaGel™ Product Benefits A practical and versatile microbicide starpharma S Evidence to date suggests that VivaGel™ is: * Potent activity against HIV/SHIV demonstrated in vitro and in vivo i * Active against other STDs ° Viral Protection . Non-toxic (e.g. HIV/SHIV) * Non-irritating * Compatible wit
Slide 11: VivaGel Commercial Strategy
VivaGel™ Commercial Strategy coh starp) arma «Initial focus on market in developed world. «Pursue HIV & Genital Herpes indications first «Subsequently: continue evaluation of product for additional indications (other STls, e.g. Chlamydia, HPV etc) «Parallel development of combination microbicides «L
Slide 12: Starpharma's Development Portfolio
Starpharma’s Development Portfolio Products and Partnered Projects Microbicides + VivaGel™ Microbicides * Pipeline of expanded «Combination microbicide (NIH) indications *Condom coatings Glycodendrimers Anti-Virals (IRL) dnfluenza “RSV Diabetes Wound Healing, (ChemGenex) Inflammation and Angiogenesi
Slide 13: Dendritic Nanotechnologies Inc. (DNT)
Dendritic Nanotechnologies Inc. (DNT) Significant Value Driver and Strategic Partner coh starp arma + Private US company dnt www.dnanotech.com + Existing revenue streams from deals with: - Dow Chemical Company, — Pfizer, Inc., — Sigma Aldrich, - US Dept. Defense * Dow recently transferred their enti
Slide 14: Recent US perspectives on Starpharma
Recent US perspectives on Starpharma coh starp arma _ “Top 5 Nanotech Breakthroughs _ for 2000 __ ‘Top Nanotech Buys for 2005” _ I ‘We expect great things to Forbes / |N come from [Starpharma] and Wolfe Repo its significant ownership in U.S.-based Dendritic Nanotechnologies, Inc.” 13
Slide 15: US demand for Starpharma shares
US demand for Starpharma shares starpharma 600000 4 500000 - _the take up of Starpharma’s ADR program since January 2005 launch _ 400000 + date is said to be “exceptional” __ Source: 300000 4 Bank of New York 5% of Starpharma shares are now _heldby USinvestors __ 200000 4 100000 - Net Depositary Rec
Slide 16: Financials and Shareholder Profile
Financials and Shareholder Profile *$8.2 million cash in the Bank (June 30) “Existing leverage of development spend through NIH grant US$5.4M and AU$5.6M of P3 funding «Several more near-term opportunities for further non-dilutive development support Shares on issue 111,235,000 Issued Capital held b
Slide 17: Starpharma: Investment Highlights
Starpharma: Investment Highlights * Dominant global position in Nanopharmaceuticals + Product focus: VivaGel™ - significant global market opportunity for HIV and other STI’s + Leverage of shareholders’ investment through public funding + Industry-leading expertise in the development of dendrimers fo
Slide 18: Growth Strategy Leadership Award
"Growth Strategy Leadership Award in the _ World Nanobiotechnology Marker”
Starpharma Holdings — Australian Biotechnology Expo 2005 on 6ix